Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-02-28

Clinical Trial Update: Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of erlotinib and bevacizumab in patients with stage IV melanoma; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bevacizumab (bevacizumab)
  • ERLOTINIB (Erlotinib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2013-02-28